Acadian Asset Management’s Albany Molecular Research Inc AMRI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q1
Sell
-421,205
Closed -$6.86M 1524
2014
Q4
$6.86M Sell
421,205
-752,538
-64% -$13.8M 0.03% 348
2014
Q3
$25.9M Sell
1,173,743
-85,506
-7% -$1.75M 0.13% 179
2014
Q2
$25.3M Hold
1,259,249
0.12% 181
2014
Q1
$23.4M Buy
1,259,249
+12,440
+1% +$171K 0.12% 163
2013
Q4
$12.6M Buy
1,246,809
+182,658
+17% +$2.21M 0.07% 222
2013
Q3
$13.7M Buy
1,064,151
+541,392
+104% +$6.66M 0.09% 194
2013
Q2
$6.2M Buy
+522,759
New +$5.66M 0.04% 271

Other funds holding AMRI

Acadian Asset Management's AMRI Position: Q1 2015 in Review

Acadian Asset Management sold out of Albany Molecular Research Inc (AMRI) in Q1 2015, closing a stake of 421,205 shares — an estimated $6.86M sold.

Acadian Asset Management first reported a position in AMRI in Q2 2013 and held it in 7 quarters. The position peaked at $25.9M in Q3 2014. 131 funds tracked by Wall St. Rank hold AMRI as of Q1 2015.

  • Acadian Asset Management reported no remaining Albany Molecular Research Inc position as of Q1 2015 after selling out during the quarter.
  • Acadian Asset Management sold 421,205 Albany Molecular Research Inc shares in Q1 2015, an estimated $6.86M.
  • Acadian Asset Management first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 7 quarters.
  • Acadian Asset Management's Albany Molecular Research Inc position peaked at $25.9M in Q3 2014.
  • 131 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2015.

Based on Acadian Asset Management's 13F filing for Q1 2015, filed 16 Apr 2015.